Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 43,500 shares of Xencor stock in a transaction dated Friday, August 18th. The stock was bought at an average cost of $19.93 per share, with a total value of $866,955.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Xencor, Inc. (NASDAQ XNCR) opened at 19.94 on Friday. The company’s market cap is $935.70 million. Xencor, Inc. has a 12 month low of $18.45 and a 12 month high of $29.38. The company’s 50-day moving average is $22.56 and its 200 day moving average is $23.00.
Xencor (NASDAQ:XNCR) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. Equities analysts forecast that Xencor, Inc. will post ($1.17) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/20/john-s-stafford-iii-buys-43500-shares-of-xencor-inc-xncr-stock.html.
A number of analysts have recently issued reports on XNCR shares. Canaccord Genuity reissued a “buy” rating and issued a $36.00 price target on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Xencor in a research report on Friday, June 16th. Finally, BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. Xencor currently has an average rating of “Hold” and a consensus price target of $29.33.
A number of large investors have recently added to or reduced their stakes in XNCR. FMR LLC boosted its stake in Xencor by 77.7% in the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after buying an additional 2,924,510 shares during the last quarter. Redmile Group LLC boosted its stake in Xencor by 59.9% in the first quarter. Redmile Group LLC now owns 1,592,526 shares of the biopharmaceutical company’s stock valued at $38,093,000 after buying an additional 596,426 shares during the last quarter. State Street Corp boosted its stake in Xencor by 17.5% in the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after buying an additional 148,136 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Xencor by 254.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 182,256 shares of the biopharmaceutical company’s stock valued at $4,797,000 after buying an additional 130,778 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Xencor by 54.5% in the first quarter. Acadian Asset Management LLC now owns 322,768 shares of the biopharmaceutical company’s stock valued at $7,722,000 after buying an additional 113,862 shares during the last quarter. Hedge funds and other institutional investors own 73.53% of the company’s stock.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
